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A Single Nucleotide Polymorphism in the MDM2
Promoter Attenuates the p53 Tumor Suppressor
Pathway and Accelerates Tumor Formation in Humans
Introduction
The tumor suppressor protein, p53, is activated upon
cellular stresses such as DNA damage and oncogene
activation and initiates a transcriptional program which
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Figure 1. The MDM2 Promoter Contains a Single Nucleotide Polymorphism Which Alters the Affinity of the Transcriptional Activator Sp1
(A) A schematic diagram depicts the intronic promoter of the MDM2 gene. The position of SNP309 is indicated in relation to the exon/intron
boundaries and the transcription factor binding sites for p53 and Ets/AP-1. The region analyzed for sequence variation is marked by the bar
drawn below the diagram.
(B) The analysis of transcription factor binding sites in the region containing SNP309 is depicted. Potential Sp1 sites are underlined.
(C) An autoradiograph of an electrophoretic mobility shift assay is depicted where varying concentrations of purified Sp1 protein were incubated
with biotin-labeled oligonucleotides containing either SNP309 (G/G; lanes 6–10), wild-type sequence (T/T; lanes 1–5), or an Sp1 optimal binding
site (lane 11, oligo alone, and lane 12, oligo and Sp1). The arrow indicates the specific Sp1-DNA complex.
(D) Chromatin immunoprecipitations (ChIP) were preformed using antibodies against either Sp1 or lamin A. The presence of the MDM2
promoter was assayed for using PCR. The PCR products are depicted here after electrophoreses on an 8% nondenaturing polyacrylamide
gel and subsequent staining with EtBr.
(E) The relative measured luciferase levels are depicted in a bar graph, whereby pGL2 luciferase reporter plasmids containing either SNP309
sequence or wild-type sequence were cotransfected with pPac (control) or pPac-Sp1 expression plasmids. Each value is the average of at
least three independent experiments and the error bars represent the standard deviations.
Results Analysis of this region of the MDM2 promoter using a
computer algorithm (AliBaba) revealed several putative
binding sites for the transcription factor Sp1 (Figure 1B).The search for genetic variation in the MDM2 promoter
was focused to a well-characterized region in the first Interestingly, the presence of SNP309, a T to G change,
extended the length of one of the putative Sp1 DNAintron of the intronic promoter, which is utilized by both
the p53 and ras pathways to activate MDM2 transcrip- binding sites, suggesting that the presence of SNP309
could increase the affinity of Sp1 to this region of thetion (Ries et al., 2000; Zauberman et al., 1995). To look
for sequence variation in this region, 300 base pairs MDM2 promoter.
In order to characterize the potential Sp1 binding sitesfrom genomic DNAs isolated from 50 healthy volunteers
were amplified by PCR and sequenced (Figure 1A). Two identified by computer analysis and to investigate the
functional consequences of SNP309, electro-mobilitysingle nucleotide polymorphisms (SNPs) were found in
this region. One of these, SNP309 (a T to G change at shift assays (EMSAs) were performed. EMSAs were car-
ried out with purified recombinant human Sp1 proteinthe 309th nucleotide in the first intron), was found at
relatively high frequency both in the heterozygous state and labeled double-stranded oligonucleotides contain-
ing either the wild-type sequence (T/T) or the SNP309(T/G, 40%) and in the homozygous state (G/G, 12%).
The other SNP, SNP344 (a T to A change at the 344th sequence (G/G). Interestingly, as predicted by the com-
puter analysis, the binding affinity of oligonucleotidesnucleotide in the first intron), is rare and is not further
studied (found only in the heterozygous state in 8% containing SNP309 to a range of concentrations (150
ng–450 ng) of purified Sp1 is much higher (2–4-fold) thanof people).
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that of the wild-type sequence (Figure 1C, lanes 2–5 (Figure 2A). MDM2 protein levels were also found to
be significantly higher (on average 4-fold) in cell linesversus lanes 7–10). The same assays were carried out
using HeLa cell nuclear extracts as a source of protein homozygous for SNP309 (G/G), as seen in the Western
blot analysis of total cell lysates (Figure 2B). Interest-instead of purified Sp1, and similar results were obtained
(data not shown). These data suggest that Sp1 can bind ingly, three of the four cell lines homozygous for SNP309
(A875, CCF-STTG1, and T47D) have been previouslyto its putative consensus site in the MDM2 promoter
and that SNP309 can greatly enhance its binding affinity reported to overexpress MDM2 when compared to cell
lines derived from similar tumor types (Landers et al.,of this site.
To verify the presence of Sp1 on the MDM2 promoter 1997; Lu et al., 2002; Phelps et al., 2003). MDM2 protein
levels were found to be intermediate in four heterozy-in vivo, a chromatin immunoprecipitation (ChIP) was per-
formed. Lysates were prepared from growing Manca gous (T/G) cell lines (MDA-231, MCF-7, WM-9, and
CACL-7336): on average 1.9-fold higher than T/T cellscells, homozygous for SNP309 (G/G), and immunopre-
cipitations were carried out using antibodies against (data not shown). Thus, together these data support an
association of SNP309 with the increased levels ofeither Sp1 or lamin A. After extensive washing and elu-
tion, the DNA was purified and the presence of the MDM2.
To test if the Sp1 transcription factor is indeed respon-MDM2 promoter was assayed for using PCR. As seen
in Figure 1D, the MDM2 promoter was detected in the sible for the heightened levels of MDM2 in cells homozy-
gous for SNP309, endogenous Sp1 was inhibited, andChIP using the Sp1 antibody (lane 3) but not using the
lamin A antibody (lane 2). These data suggest that Sp1 the resulting effect on endogenous MDM2 levels was
analyzed. Sp1 was inhibited using two different ap-binds this region of the MDM2 promoter in vivo.
To investigate a possible role of Sp1 in the transactiva- proaches. First, Sp1 levels were reduced by transfecting
siRNAs specific to Sp1 RNA. Second, Sp1 activity wastion of the MDM2 promoter and the influence of SNP309,
Drosophila SL2 cells, which are deficient in Sp-related inhibited by treating cells with mithramycin A, an aureo-
lic antibiotic that has been shown to selectively inhibitproteins, were utilized. SL2 cells were transiently trans-
fected with an Sp1 expression vector (pPac-Sp1) and a Sp transcription factor-mediated transcriptional activa-
tion (Blume et al., 1991).luciferase reporter plasmid driven by the MDM2 pro-
moter either wild-type (T/T) or homozygous (G/G) for Sp1 siRNA reduced the protein levels of Sp1 over
2-fold in all three cell lines tested, as shown in FiguresSNP309. As shown in Figure 1E, cotransfection of Sp1
strongly stimulated luciferase expression of the reporter 3A and 3B, when compared to Sp1 levels in cells trans-
fected with either a nonspecific siRNA (NS, Figure 3A,plasmid driven by the MDM2 promoter, as measured by
luciferase activity, suggesting that Sp1 can bind to this lanes 3, 6, and 9) or siRNAs targeted against lamin A/B
transcripts, although lamin A/B protein levels were dra-region of the MDM2 promoter and activate transcription.
Interestingly, the presence of SNP309 in the reporter matically reduced (Figure 3A, lanes 1, 4, and 7). Sp1
siRNA had no effect on another Sp family member, Sp3plasmid consistently showed higher Sp1-induced lucif-
erase expression (50%) over the presence of wild- (Figure 3A). As expected, reduction of Sp1 levels lead
to the reduction of the protein levels of one of its knowntype sequence in the reporter plasmid, as the increased
binding affinity of Sp1 to SNP309-containing oligonucle- target genes, cyclin D1, in all three cell lines tested
(Figure 3A; Grinstein et al., 2002). As predicted, reduc-otides would have predicted. Similar results were ob-
tained when both reporter plasmids were transfected tion of Sp1 levels dramatically decreased MDM2 levels,
up to 3-fold in cells homozygous for SNP309 (A875 andinto the mammalian HeLa cell line which has an abun-
dance of Sp1. The reporter plasmid containing SNP309 T47D), while in cells wild-type for SNP309 (HeLa), reduc-
tion of Sp1 levels had no significant effect on MDM2(G) yielded significantly higher luciferase levels (60%)
than the plasmid containing the wild-type sequence (T) levels (Figures 3A and 3B). Inhibition of Sp1 activity by
treating cells with mithramycin A showed similar effects(data not shown).
Together, these data suggest that Sp1 can bind to on MDM2 levels. A cell line homozygous for SNP309
(T47D) and a cell line wild-type for SNP309 (HL60) werethe MDM2 promoter and activate transcription and that
the presence of SNP309 further stimulates the activity of treated with various concentrations of mithramycin A
for 24 hr, and MDM2 protein levels were analyzed asSp1 by enhancing its DNA binding affinity to the MDM2
promoter. If true, individuals homozygous for SNP309 shown in Figure 3C. In cells homozygous for SNP309
(T47D), mithramycin A treatment significantly decreased(G/G) should show heightened levels of MDM2 when
compared to individuals wild-type for SNP309 (T/T). To MDM2 levels. Specifically, 200 nM mithramycin A re-
duced MDM2 levels more than 5-fold in T47D, while noaddress this, cells in culture were employed. Forty-three
tumor-derived cell lines were genotyped for SNP309. significant effect was seen in cells wild-type for SNP309
(HL 60). Similar effects were seen in other cell lines asSNP309 was present at a frequency similar to that found
in the normal volunteers. MDM2 RNA and protein levels shown in Figure 3D. In two more cell lines homozygous
for SNP309 (Manca and A875), mithramycin A treatmentwere compared in four cell lines homozygous for
SNP309 (G/G) to the levels found in four cell lines wild- significantly decreased MDM2 levels. However, mithra-
mycin A only slightly reduced the MDM2 levels in twotype for SNP309 (T/T). To compare MDM2 RNA levels,
total RNA was isolated from growing cells. MDM2 RNA more cell lines wild-type for SNP309 (HeLa and ML-1).
In summary, both methods of Sp1 inhibition can prefer-levels were measured by real-time PCR (TaqMan). The
presence of SNP309 correlated with high expression of entially reduce the heightened levels of MDM2 in cells
homozygous for SNP309, thereby supporting the hy-the MDM2 transcript (on average 8-fold) when compared
to the levels seen in cells wild-type for SNP309 (T/T) pothesis that the Sp1 transcription factor is indeed re-
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Figure 2. SNP309 Associates with the Overexpression of MDM2
(A) The levels of MDM2 RNA from tumor-derived cell lines are shown as measured by real-time PCR (TaqMan). All values have been normalized
to the level of GAPDH and are the averages of three independent readings. The standard deviation is given in the parenthesis next to each value.
(B) A Western blot analysis of MDM2 levels found in total cell lysates is shown. The upper panel is a Western blot using a monoclonal MDM2
antibody (SMP-14). Full-length MDM2 protein runs as a doublet and is indicated by arrows. The middle panel is a Western blot of the same
filter using a monoclonal antibody to p53 (Do-1) and the lower panel is a Western blot of the same filter using a monoclonal antibody to actin.
sponsible for the heightened levels of MDM2 in cells blocking Sp1-mediated transcription by mithramycin A
treatment, and the activity of the p53 pathway was as-homozygous for SNP309.
Overexpression of MDM2 can lead to the inactivation sessed by measuring the apoptotic response after DNA
damage (etoposide treatment). Specifically, Manca (ho-of the p53 pathway (Lain and Lane, 2003). We therefore
reasoned that the SNP309-homozygous cell lines, with mozygous for SNP309) and ML-1 (wild-type for SNP309)
were treated with various concentrations of mithramycinhigher levels of MDM2, should have an attenuated p53
response. To test the p53 response, these cells were A and etoposide for 48 hr, after which the percentage
of cells undergoing apoptosis was measured. Interest-treated with the chemotherapeutic drug etoposide
(VP16) to induce DNA damage. This DNA damage acti- ingly, as shown in Figure 4B, the percentage of etopo-
side-induced cell death increased significantly (2–3 fold)vates the p53 pathway, leading to DNA repair, cell cycle
arrest, and apoptosis. Significant death (20%–35% of in Manca (SNP309 homozygous cell line) with mithra-
mycin A treatment. However, in ML-1 (SNP 309 wild-the total cell population) was observed in cells that are
wild-type at p53 and wild-type for SNP309 (T/T) (H460, type cell line), mithramycin A treatment had no obvious
effect on etoposide-induced cell death. Similar resultsML-1, Tera-2: Figure 4A, lanes 1–3). Interestingly, cells
with wild-type p53 that are homozygous for SNP309 were obtained using various incubation times (data not
shown). These data demonstrate that reduction of(G/G) (Manca, CCF-STTG1, and A875: Figure 4A, lanes
6–8) showed much lower death rates (on average MDM2 levels by inhibiting Sp1 activity can reverse the
attenuated p53 response in the SNP309 homozygous2%–3% of the total cell population). In fact, the percent-
age of cells dying after treatment was similar to that cell lines, thereby supporting the model that the height-
ened MDM2 levels due to increased Sp1 activity on theseen in cells either mutant (T47D) or null (Saos2) for the
p53 gene itself (compare lanes 5 and 4 with 1–3). Four MDM2 promoter in SNP309 cells result in the attenuation
of the p53 pathway.cell lines heterozygous for SNP309 (T/G) and wild-type
for p53 were also assayed for their response to etopo- p53 responds to DNA damage by activating a tran-
scriptional program (Jin and Levine, 2001). If the lowside and found to be intermediate in their response: on
average 5%–7% of the total cell population (data not death rates, seen after etoposide treatment in the homo-
zygous SNP309 cell lines, is due to inhibition of p53,shown). Together, these data demonstrate that the DNA
damage response pathway is attenuated in the SNP309 the p53 transcriptional program should be weakened in
these cells. To test this, cells with wild-type p53 werehomozygous cell lines.
These data support the model that the heightened treated with etoposide, and then the induction of 27
known p53-responsive genes was compared in the cellsMDM2 levels in SNP309 cells attenuate the p53 pathway.
If true, reducing the MDM2 levels should allow for the either homozygous for SNP309 or wild-type for SNP309.
RNA was isolated from cells before and after etoposidep53 pathway to be activated in the SNP309 homozygous
cells lines. To test this, MDM2 levels were reduced by treatment, and gene expression was analyzed using the
A SNP in Mdm2, the p53 Pathway, and Tumor Formation
595
Figure 3. Inhibition of Endogenous Sp1 Can Reduce the Heightened Levels of Endogenous MDM2 in Cells Homozygous for SNP309
(A) Cell lines homozygous for SNP309 (G/G; A875 and T47D) and wild-type for SNP309 (T/T; HeLa) were transfected with siRNA specific for
Sp1, for lamin A/B, or a nonspecific siRNA (NS). Depicted here are autoradiographs of Western blots using antibodies specific for Sp1, Sp3,
MDM2, cyclin D1, lamin A/B, and Gapdh. Arrows indicate the positions of the proteins.
(B) The bar graphs represent the quantification of Western blot analysis in (A). The relative expression levels in cells transfected with siRNA
for Sp1 was determined as the percentage of either Sp1 or MDM2 in the cells transfected with Sp1-siRNA to those transfected with nonspecific
siRNA. Each value is the average of at least three independent experiments and the error bars represent the standard deviations.
(C and D) Cell lines either homozygous for SNP309 (G/G; T47D, A875, and Manca) or wild-type for SNP309 (T/T; HL60, H460, and Ml-1) were
treated with various concentrations of mithramycin A for 24 hr. Autoradiograms of Western blots using either MDM2 or Gapdh antibodies are
shown. Arrows indicate the positions of the proteins.
AffyMetrix GeneChip array (Human Genome U95A Array). proteosamal degredation (Haupt et al., 1997; Honda et
al., 1997; Kubbutat et al., 1997). Upon certain cellularCells wild-type for SNP309 induced multiple known p53-
responsive genes above 5-fold (Figure 4C). Specifically, stresses, such as DNA damage, p53 levels rise, as the
half-life of p53 dramatically increases. The increase ofnine genes in the lung carcinoma cell line, H460 (Figure
4C, lane 1), six genes in the myeloid leukemic cell line, the half-life of p53 has been attributed to the inability of
MDM2 to target p53 for degradation after DNA damage.ML-1 (Figure 4C, lane 2), and four genes in the testicular
teratoma cell line, Tera-2 (Figure 4C, lane 3), were in- Specifically, immediately after DNA damage, MDM2 lev-
els decrease dramatically as does its affinity for p53duced. In contrast, cells homozygous for SNP309 showed
a much-weakened p53-dependent transcriptional re- binding (Michael and Oren, 2003).
To address what effect the elevated MDM2 levels insponse. The melanoma cell line, A875 (Figure 4C, lane 4),
did not induce any known p53-responsive gene above G/G cells have on p53 levels, the levels of wt p53 in
cells before and after stress (DNA damage) were moni-5-fold and both the astrocytoma cell line, CCF-STTG1
(Figure 4C, lane 6), and the Burkitt’s lymphoma cell line, tored. As seen in Figure 2B there are no significant differ-
ences in basal wild-type p53 levels between cells wild-Manca (Figure 4C, lane 5), only induced one gene above
5-fold. These data demonstrate that the ability of p53 type or homozygous for SNP309 (compare p53 levels
in lanes 1, 2, and 3 to those in lanes 5, 7, and 8). To ruleto act as a transcriptional activator for known target
genes is attenuated in cells homozygous for SNP309. out the possibility that MDM2 cannot target p53 for
degradation in G/G cells, MDM2 levels were artificiallyTaken together, these data support a model that cells
homozygous for SNP309 (G/G) express higher levels of reduced in nonstressed cells, and p53 levels were moni-
tored. As seen in Figure 4D, reduction of MDM2 levels,MDM2, thereby attenuating the p53 pathway. MDM2 has
been shown to inhibit p53 minimally by three different using siRNAs, in the two G/G cell lines tested led to
the significant stabilization of p53. The stabilized p53 ismechanisms. One well-studied mechanism is its ability
to serve as an E3 ubiquitin ligase, targeting p53 for active, as p21 levels also rise, and p21 is a well-known
Cell
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Figure 4. p53 Activity Is Attenuated in Cells Homozygous for SNP309
(A) In the bar graph, the percent of the population of cells which are dead after 24 hr of either 1 M (black) or 5 M (gray) etoposide treatment
is plotted for each cell line. Each value is the average of three independent experiments and the error bars represent the standard deviations.
(B) Inhibition of Sp1 activity by mithramycin A treatment increases DNA damage-induced cell death in cells homozygous for SNP309. Manca
(homozygous for SNP309) and ML-1 (wild-type for SNP309) were treated with either 1 M (black) or 5 M (gray) etoposide and various
concentrations of mithramycin A for 48 hr. The percentage of the dead cell induced by etoposide and mithramycin A treatment was measured
and subtracted with any death induced by mithramycin A treatment alone. Fold induction of cell death is depicted in the bar graph. Each
value is the average of at least three independent experiments and the error bars represent the standard deviation.
(C) In the bar graph, the number of known p53 target genes induced after DNA damage (etoposide treatment) above 5-fold from levels found
in untreated cells is plotted for each cell line.
(D) MDM2 can inhibit p53 in cell lines homozygous for SNP309 (G/G; A875 and CCF). Cells were transfected with siRNA specific for MDM2,
for lamin A/B or a nonspecific siRNA (NS). Depicted here are autoradiographs of Western blots using antibodies specific for MDM2, p53, p21,
and Gapdh.
p53 transcriptional target. These data suggest that above after only 1 hr of etoposide treatment. Interest-
ingly, there was no significant stabilization of p53 in cellsMDM2 can target p53 for degradation in G/G cells, but
that, in nonstressed cells, heightened levels of MDM2 homozygous for SNP309 (G/G) in the times tested. These
data support the hypothesis that the heightened levelsin G/G cells do not further reduce the levels of wt p53.
As mentioned above, the heightened MDM2 levels of MDM2 in SNP309 cells result in the inability to properly
stabilize p53 in response to cellular stresses like DNAcould also inhibit the proper stabilization of p53 in re-
sponse to stress, thereby attenuating the p53 pathway. damage but that the heightened levels of MDM2 do not
further reduce the levels of wt p53 in nonstressed cells.To address this possibility, the stabilization of p53 after
etoposide treatment was monitored (Figures 5A and 5B). The inability to properly stabilize p53 in response to
DNA damage provides one possible mechanism for theCells were treated with etoposide and harvested after
1, 2, and 3 hr of treatment. The p53 levels were measured observed attenuation of p53 pathway in cells homozy-
gous for SNP309 (G/G).by Western blotting and the fold induction of p53 levels
after etoposide treatment was calculated for each cell The data thus far support a model that cells homozy-
gous for SNP309 express higher levels of MDM2,line and each time point. The values are depicted in the
bar graph in Figure 5B. As expected, the p53 levels in thereby weakening the p53 pathway. Humans who carry
a germline p53 mutation in one allele (Li-Fraumeni Syn-cells wild-type for SNP309 (T/T) increased 4-fold or
A SNP in Mdm2, the p53 Pathway, and Tumor Formation
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Figure 5. The Stabilization of p53 after DNA Damage Is Impaired in Cells Homozygous for SNP309, and the p53 DNA Damage Response Is
Attenuated in Li-Fraumeni Fibroblasts Homozygous for SNP309 with High MDM2 Levels
(A) Cell lines either wild-type (T/T) or homozygous (G/G) for SNP309 were treated with etoposide and harvested after 1, 2, and 3 hr of treatment.
Depicted here are autoradiographs of Western blots using antibodies specific for p53 and ran. The autoradiograms are depicted, and exposures
were chosen to highlight the induction of p53 after etoposide treatment for each cell line. The p53 levels were measured and normalized to
ran levels from the autoradiograms in (A), and the fold induction of p53 after etoposide treatment from basal levels was calculated for each
cell line and each time point. The values are depicted in the bar graph in (B).
(C) A Western blot analysis of MDM2 levels found in total cell lysates is shown. The upper panel is a Western blot using a monoclonal MDM2
antibody. Full-length MDM2 protein is indicated an arrow. The lower panel is a Western blot of the same filter using a monoclonal antibody
to ran.
(D) The fibroblastoid cell line derived from a germline p53 mutation carrier (Li-Fraumeni) and homozygous for SNP309 has an altered DNA
damage response when compared to Li-Fraumeni fibroblastoid cell lines wild-type for SNP309. Histograms are depicted of the DNA content
in cells after 24 hr of varying concentrations of etoposide treatment (0, 1, and 5 M, indicated above the panels).
drome) develop tumors at very high frequencies (Garber lines, the G/G fibroblasts showed significantly higher
MDM2 levels (above 3-fold) when compared to thoseet al., 1992; Li et al., 1990). These individuals develop
tumors on average at very young ages and can develop found in both T/T fibroblast cell lines (Figure 5C). Upon
etoposide treatment, the two fibroblast cell lines wild-multiple primary tumors throughout a lifetime. We hy-
pothesized that increased levels of MDM2 by SNP309 type for SNP309 (T/T) showed a characteristic p53-
mediated G2 arrest as noted by the accumulation ofcould further weaken the p53 pathway in Li-Fraumeni
individuals and further impact tumorigenesis. To test cells with tetraploid DNA content (Figure 5D). In contrast,
the fibroblast cell line homozygous for SNP309 (G/G)this, the first approach was to analyze MDM2 levels
and the DNA damage response (etoposide treatment) did not show such a response. In fact, no significant
difference in the DNA content of the SNP309 homozy-in fibroblasts derived from Li-Fraumeni individuals who
were either wild-type for SNP309 (T/T) or homozygous gous (G/G) cells was seen. These data suggested that
both MDM2 levels and the p53 pathway in Li-Fraumenifor SNP309 (G/G). MDM2 levels were analyzed by West-
ern blotting for two fibroblast cell lines wild-type for individuals, as measured by the DNA damage response
in fibroblasts, could be greatly affected by the presenceSNP309 (T/T) and one fibroblast cell line derived from
the Li-Fraumeni individual homozygous for SNP309 of SNP309.
If SNP309 further debilitates the p53 pathway in Li-(G/G). As predicted by the analysis of tumor-derived cell
Cell
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Figure 6. SNP309 Associates with an Accelerated Age of Onset of Tumors and the Occurrence of Multiple Subsequent Tumors in Li-
Fraumeni Individuals
(A) Of the 88 individuals in the Li-Fraumeni cohort, 66 were diagnosed with at least one cancer at a median age of 22 years old. The first
cancers the 66 individuals were diagnosed with are shown in the pie chart. Individuals either T/G or G/G are diagnosed on average 7 years
earlier than wild-type (T/T) individuals as depicted in (B). The cumulative number of individuals either with SNP309 (heterozygous or homozygous)
(circles) or wild-type for SNP309 (triangles) is plotted against the age of onset of STS (C) and breast cancer (D).
(E) The bar graph depicts the number of individuals who were first diagnosed with STS (black) and then with subsequent cancers (second,
third, fourth, and fifth) for individuals either wild-type (T/T), heterozygous (T/G), or homozygous (G/G) for SNP309.
Fraumeni individuals, tumor development might also be ingly, individuals who carried SNP309, in either the het-
erozygous or homozygous state, showed a significantlyaffected. To address this possibility, 88 individuals who
are members of Li-Fraumeni families and have germline earlier age of onset for all tumor types (Figure 6B). For
individuals with SNP309, the median age of tumor onsetmutations in one allele of p53 were studied, and the
frequency of SNP309 was found to be similar to the was 18 years old, while in wild-type individuals the me-
dian age of tumor onset was 27 years old (p  0.031).frequencies found in the 50 normal volunteers (Hwang
et al., 2003). Sixty-six have been diagnosed with at least Specifically, the median age of onset of STS in wild-
type individuals was fourteen years old, while in SNP309one cancer so far. Soft tissue sarcomas (STS) (20 individ-
uals), breast cancer (17), and osteosarcomas (13) were individuals the median age of onset was two years old
(p  0.019, Figure 6C). In those who developed breastthe most prevalent first cancers (Figure 6A). Interest-
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cancer, the median age of onset in wild-type individuals in cell culture systems demonstrate that SNP309 in the
promoter of the MDM2 gene increases the binding affin-was 39 years old, and in SNP309 individuals the median
ity of the transcriptional activator Sp1, which results inage of onset was 29 years old (p  0.01, Figure 6D).
high levels of MDM2 RNA and protein. The heightenedTaken together, those carrying SNP309 developed all
MDM2 levels were shown to lead to the attenuation oftumor types 9 years earlier, STS on average 12 years
the p53 DNA damage response, in concordance with theearlier and breast cancer on average 10 years earlier
observations that MDM2 is as a key negative regulatorthan those who do not carry SNP309. These data sup-
of p53. The results of clinical epidemiological studiesport the hypothesis that the presence of SNP309 further
demonstrated that SNP309 associates with minimally adebilitates the p53 pathway in Li-Fraumeni individuals,
9-year earlier onset of tumors in both hereditary andresulting in an even earlier tumor onset.
sporadic cancers. Together, these data support a modelAs mentioned above, another hallmark of the Li-
whereby SNP309 enhances the affinity of the transcrip-Fraumeni syndrome is the occurrence of multiple pri-
tional activator Sp1 to the promoter of the MDM2 gene,mary tumors in a lifetime. Interestingly, the presence of
resulting in heightened transcription. Heightened levelsSNP309 also correlated with the occurrence of multiple
of MDM2 lead to the direct inhibition of p53, which re-tumors in those individuals first diagnosed with STS (p
leases the cell from p53 tumor suppression. Inhibition0.0014, Fisher’s exact test, Figure 6E). Specifically, both
of endogenous Sp1 using either siRNA or mithramycinindividuals homozygous for SNP309 (G/G) developed a
A can significantly reduce SNP309-related overexpres-second and a third cancer, and one developed a fourth
sion of MDM2. The experiments presented here demon-and a fifth cancer. Of the nine people heterozygous for
strate that reduction of SNP309-related overexpressionSNP309 (T/G), seven developed a second cancer, four
of MDM2 by mithramycin A treatment can reverse thea third, and one a fourth and a fifth cancer. In contrast,
attenuated p53 response. Mithramycin A is an aureolicof the nine people wild-type for SNP309 (T/T), only two
antibiotic that has been used in humans to treat severaldeveloped a second cancer and none a third, a fourth,
types of cancer and hypercalcemia associated with can-or a fifth cancer. These data indicate an association
cers (Hurtado and Esbrit, 2002). The data presented herewith the presence of SNP309 and the occurrence of
suggest that treating cancer patients homozygous forindependent subsequent cancers. Together, these data
SNP309 with mithramycin A may enhance their responsesupport a model whereby the presence of SNP309 in
to chemotherapeutic drugs by reducing MDM2 levelsthe promoter of the MDM2 gene leads to overexpression
to allow for a p53-dependent apoptotic response in-of the MDM2 protein, which then inhibits p53 and im-
duced by most chemotheraputic agents.pacts two major hallmarks of the Li-Fraumeni Syndrome,
The model proposed here states that the heightenednamely the early age of onset of tumors and the occur-
levels of MDM2, due to SNP309, result in acceleratedrence of multiple primary tumors in a lifetime.
tumor formation in humans. There is much evidence inThe next question raised was if SNP309 caused a
the literature to support the claim that high MDM2 levelsweakened p53 pathway, did this SNP act upon sporadic
can positively impact tumorigenesis. For example,cancers as well as genetically altered individuals with a
Jones et al. (1998) created mice which overexpressp53 defect. To address this question, a group of patients
Mdm2 by using the entire MDM2 gene as a trans-gene.who develop sporadic adult STS and had no known
These mice expressed an average of 4-fold more Mdm2hereditary cancer predisposition and no known germline
in various tissues relative to nontransgenic mice. Inter-p53 mutation was studied. As seen in the pie chart in
estingly, 100% of the Mdm2-overexpressing mice devel-Figure 7A, the sarcomas come from a variety of tissues.
oped spontaneous tumors in a lifetime. Lundgren etInterestingly, as in the Li-Fraumeni individuals, SNP309
al. (1997) also showed that targeted overexpression ofassociates with an earlier age of onset of STS (Figure
Mdm2 in the murine mammary epithelium results in tu-7B). Specifically, those individuals homozygous for
mors, albeit with a lower penitence (16%). These two
SNP309 were diagnosed on average 12 years earlier
studies, together with numerous accounts of MDM2
than those individuals without SNP309 (p  0.01, Figure
overexpression or amplification in a variety of human
7C). As seen in Figure 7D, the frequency of the SNP309 cancers, support the idea that heightened levels of
G allele was greatly increased in those individuals who MDM2, by SNP309, could positively impact tumor for-
developed STS at a young age. Those who developed mation (Cordon-Cardo et al., 1994; Momand et al., 1998;
STS below the age of 41 years old had an allele fre- Oliner et al., 1992; Taubert et al., 2000).
quency for SNP309 of 50%, while the allele frequency MDM2 is a key negative regulator of p53. MDM2 can
is only 33% for the whole group (p  0.0262, Figure 7D). regulate the degradation of p53 as an E3 ubiquitin ligase,
These data demonstrate that SNP309 does not require targeting p53 for proteosamal degredation (Michael and
the presence of an inactivating germline p53 mutation Oren, 2003). Observations in this report support the hy-
to associate with earlier STS tumor formation. pothesis that the heightened levels of MDM2 in SNP309
cells (G/G) result in the inability to properly stabilize p53
Discussion in response to cellular stresses like DNA damage; this
hypothesis offers one possible mechanism of p53 atten-
Experimental data have been presented in this report uation by MDM2 in SNP309 (G/G) cells. Interestingly,
which support the hypothesis that single nucleotide the heightened levels of MDM2 do not further reduce
polymorphisms in the tumor suppressor p53 pathway the levels of wild-type p53 in nonstressed cells. One
can be a part of the genetic variation which underlies the explanation for these observations is that the ability of
phenotypic variation seen in individuals’ susceptibility to MDM2 to regulate p53 levels may not be limiting in
nonstressed cells, so heightened levels of MDM2 wouldcancer. To summarize, the results in biochemical assays
Cell
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Figure 7. SNP309 Associates with an Accelerated Age of Onset of Tumors in Sporadic Soft Tissue Sarcoma
(A) The subtypes of STS are depicted in the pie chart. Individuals homozygous for SNP309 showed a significantly earlier age of onset of STS,
on average 12 years earlier (B). The cumulative number of individuals either homozygous for SNP309 (circles) or wild-type for SNP309 (triangles)
is plotted against the age of onset of STS (C).
(D) SNP309 is at a higher frequency in the population with early onset STS. The cumulative number of individuals either homozygous for
SNP309 (circles), heterozygous for SNP309 (squares), or wild-type for SNP309 (triangles) is plotted against the age of onset of STS in those
who were diagnosed below the age of 41 years old (one standard deviation from the median age of onset).
(E) SNP309 could serve as a rate-limiting event in liposarcoma. The number of rate-limiting events required to create a cancer cell and
subsequent tumor was calculated using I(t)  kt r1, whereby r is the number of rate-limiting events. The R value was calculated for each
genotype by plotting the cumulative number of individuals either homozygous for SNP309 (circles), heterozygous for SNP309 (squares), or
wild-type for SNP309 (triangles) against the age of onset of liposarcoma and performing a nonlinear regression as a power function to obtain
the exponent for each curve. The equations for the trend-line, R2 value, and R value are displayed for each genotype.
have no further impact on p53 levels. Only when MDM2 dence of many tumors increases with the power of age,
and it was proposed that the age-specific increase couldactivity is reduced after cellular stress (or artificially,
e.g., siRNA in nonstressed cells, Figure 4D) does MDM2 be correlated to the number of rate-limiting steps in-
volved in the formation of a cancer cell and subsequentbecome limiting, where heightened MDM2 levels would
result in less induced p53 (Figures 5A and 5B). tumor. Specifically, the function I(t)  ktr1 was used to
describe the incidence of cancer (I) observed at a givenThe results presented in this report suggest that
SNP309 can impact tumorigenesis in humans who carry age (t), whereby r is the number of rate-limiting events
which have to occur in cells at the constant rate (k). Thisa germline inactivating mutation in one p53 allele (Li-
Fraumeni Syndrome). The data suggest that SNP309 equation or derivatives thereof have been successfully
used to describe many cancers (Knudson, 2001), mostcan further lower the age of onset of tumors in these
individuals on average 9 years and increase the occur- notably in Alfred G. Knudson’s description of hereditary
and nonhereditary forms of retinoblastoma, which laterrence of multiple primary tumors in a lifetime. One possi-
ble scenario to explain these observations is that high became known as the two hit theory. As shown in Fig-
ures 6 and 7, the age-incidence curves of those patientslevels of MDM2 and just one wild-type p53 allele in those
Li-Fraumeni individuals with SNP309 produce a severely with SNP309 (G/G) vary greatly from those individuals
with a genotype of T/T or even T/G. Interestingly, whenweakened p53 tumor suppressor pathway resulting in
a higher mutation rate, poorer DNA repair processes, the number of rate-limiting events (R value) is calculated
for each genotype at the SNP309 locus in sporadic lipo-and reduced apoptosis leading to faster and more fre-
quent tumor formation. sarcomas, T/T gives a value of 4.8, T/G 3.5, and G/G
2.5 (Figure 7E). The fact that the heterozygote reducesFifty years ago it was noted that age-specific inci-
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by tandemly inserting two copies of double-stranded oligonucleo-the R value by one and the homozygote by two suggests
tides containing the same sequence as used for the EMSAs intothat the G allele can serve as a rate-limiting event in the
pGL2 luciferase reporter plasmid (Promega). The clones were con-formation of a sarcoma.
firmed by DNA sequencing.
It is not difficult to propose a model to explain why Drosophila Schneider’s SL2 cells were seeded at 1.5  106 cells
SNP309 could be a rate-limiting event in carcinogenesis. per well in a six-well plate 24 hr before transfection. Transient trans-
fections were preformed using CellfectAMINE (Invitrogen) accordingOver the past 50 years, it has become clear that age-
to the manufacturer’s instructions. The DNA transfection mixturespecific incidence of cancer is dependent minimally on
contained 250 ng reporter plasmid, varying amounts of pPac-Sp1three factors: the number of rate-limiting mutations re-
plasmid, and empty pPac vector to normalize DNA concentrations.quired for a given cancer, the mutation rate per mitosis,
The expression plasmids pPac and pPac-Sp1 were kindly provided
and the net proliferation rate of the effected cells (cell by Dr. Richard D. Kolodoner (La Jolla, California). Cells were har-
division rate minus cell death rate; Knudson, 2001). Inhi- vested 48 hr after transfection in reporter lysis buffer (Promega)
and assayed for luciferase activity. Each extract was analyzed inbition of the p53 pathway by SNP309 could potentially
duplicate, and at least three independent experiments were per-affect all three of these factors (Jin and Levine, 2001;
formed. Luciferase activities were normalized to cellular protein,Lain and Lane, 2003). The p53 gene itself is thought of
measured by the Bio-Rad protein assay system.as a rate-limiting mutation in many cancer types, as it
is found mutated in over 50% of all human tumors, and RNA Analysis
humans who carry a germline p53 mutation develop To analyze MDM2 RNA levels, total RNA was isolated from cell
cancer with increased incidence and on average early pellets using RNeasy (Qiagen). cDNAs were made using TaqMan
reverse transcription reagents from Applied Biosystems. Real-timein life. The wild-type p53 pathway is also thought to
PCR was carried out using the ABI Prism 7000 sequence detectionreduce mutation rates per mitosis, as loss of p53 leads
system. Probe and primer sets for MDM2 and Gapdh were pur-to defective centrosome replication and numerous chro-
chased as predeveloped assays from Applied Biosystems.
mosomal abnormalities. Finally, the p53 pathway also
impacts the net proliferation rate of cells, as it functions Protein Analysis
to arrest the cell cycle and induce apoptosis upon stress To analyze protein levels, total cell extracts were made by using a
signals like DNA damage and oncogene activation. detergent lysis buffer (50 mM Tris [pH 7.5] 150 mM NaCl, 1% NP40,
0.1% SDS, 0.5% deoxycholic acid, 5mM EDTA, and a proteaseTherefore, inhibition of the p53 pathway by SNP309
inhibitor cocktail [Complete Mini, Roche]). Thirty micrograms of totalcould affect all three factors, which have been shown
protein was run on a 4%–20% tris-glycine gel (Invitrogen) and trans-to influence the age-specific incidence of cancer to ac-
ferred to a PVDF membrane. MDM2 was detected using the mouse
celerate carcinogenesis in an individual. monoclonal antibody SMP-14; Sp1 and Sp3 were detected using
the rabbit polyclonal antibody PEP2 and D-20, respectively. Lamin
Experimental Procedures A/C, cyclin D1, p53, and actin were detected using the mouse mono-
clonal antibody 346, DCS-6, Do-1, and C-2, respectively. Gapdh
Sequence Analysis was detected using the goat polyclonal antibody V-18. All antibodies
The MDM2 promoter was analyzed for sequence variation by PCR were purchased from Santa Cruz.
amplification and subsequent sequencing, primer 1: CGGGAGTT
CAGGGTAAAGGT and primer 2: AGCAAGTCGGTGCTTACCTG.
Gene Silencing with siRNA
Sp1 siRNA targeted to AATGAGAACAGCAACAACTCC was used to
Electrophoretic Mobility Shift Assays (EMSA)
lower Sp1 expression. Two hundred picomoles siRNA duplex was
EMSAs were performed with a LightShiftTM Chemiluminescent
transfected into cells at 30%–50% confluencey using oligofectamine
EMSA Kit (PIERCE, Rockford, Illinois). The binding reactions were
reagent (Invitrogen) according to the manufacturer’s instructions.
performed for 20 min at room temperature in 10 mM Tris-HCl ([pH
Control siRNA duplex has no known target in mammalian genomes
7.5] at 25C), 1 mM MgCl2, 50 mM NaCl, and 0.5 mM DTT, 4% and was used as follows: sense UUCUCCGAACGUGUCACGUdTdT,
glycerol, 50 g/ml poly (dI-dC) (dI-dC), 10 fmol biotin 3-end-labeled
antisense ACGUGACACGUUCGGAGAAdTdT. Lamin A/C siRNAs
double-stranded oligonucleotides, and purified recombinant Sp1
were purchased from Qiagen and MDM2 siRNAs from Dharmacom.
protein. After incubation, samples were separated on a native 4%
Cells were lysed 48 hr after transfection, and protein levels of Sp1,
polyacrylamide gel and then transferred to a nylon membrane. The
Sp3, and MDM2 were analyzed as described above.
positions of the biotin end-labeled oligonucleotides were detected
by a chemiluminescent reaction with streptavidin-horseradish per-
Mithramycin A Treatmentoxidase according to the manufacturer’s instruction and visualized
Logarithmically growing cells were treated with various concentra-by autoradiography. The nucleotide sequence of the double-
tions of mithramycin A (Sigma) for 24 hr. After treatment, cells werestranded oligonucleotides with either wild-type sequence or the
lysed and protein levels of MDM2 were analyzed.SNP is as follows: 5-CCGGGGGCTGCGGGGCCGCTT/GCGGCGC
GGGAGGTCCGGATG-3.
Cell Viability Analysis
To analyze induction of cell death after etoposide treatment, growingChromatin Immunoprecipitation
cells were treated with either 1 M or 5 M etoposide for 24 hr. ToProteins were crosslinked to DNA in 1% formaldehyde. After wash-
analyze etoposide-induced cell death after inhibition of Sp1, grow-ing, cells were lysed in detergent lysis buffer. Lysates were washed
ing cells were treated with various concentrations of mithramycinand sonicated. Two micrograms of antibodies were added and incu-
A and etoposide for 48 hr. After treatment, cells were harvested andbated overnight. Protein A/G Plus beads (Santa Cruz) were used,
viability was measured using the Guava ViaCount assay (Guava).and after extensive washing, crosslinks were removed at 65C over-
night in an elution buffer (1% SDS, 0.1 M NaHCO3). DNA was isolated
Cell Cycle Analysisusing the QIAquick PCR purification kit (Qiagen). Ten percent of
To analyze the DNA damage response in fibroblasts, all cells werepurified DNA was analyzed by PCR. The entire PCR reaction was
treated with two concentrations of etoposide (1 M and 5 M) foranalyzed by gel electrophoreses on an 8% nondenaturing polyacryli-
24 hr. Cells were harvested and fixed with methanol and keptmide gel and subsequent ethidium bromide staining.
at 20C for 40 min or overnight. After washing and equlibration in
PBS, the cell pellet was resuspended in 1 ml of staining solutionLuciferase Reporter Assays
containing 50 g of RNase A and 0.5 g of propidium iodide perThe MDM2 promoter-luciferase reporter plasmids containing either
the wild-type sequence or the SNP309 sequence were constructed ml in PBS and kept at room temperature for over 30 min. The cells
Cell
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were then applied to the fluorescence-activated cell sorter (FACS- dent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA
95, 15608–15612.Calibur; Becton Dickson). The FACSCalibur program was used to
sort and count the cells. Knudson, A.G. (2001). Two genetic hits (more or less) to cancer.
Nat. Rev. Cancer 1, 157–162.
Statistical Analysis Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation
A randomization test is employed to determine the statistical signifi- of p53 stability by Mdm2. Nature 387, 299–303.
cance of the age of onset of cancer between the groups with and
Lain, S., and Lane, D. (2003). Improving cancer therapy by non-without SNP309. The two groups are compared pair-wise, and each
genotoxic activation of p53. Eur. J. Cancer 39, 1053–1060.instance of an element from the second group greater than an ele-
Landers, J.E., Cassel, S.L., and George, D.L. (1997). Translationalment of the first group adds one to the distance. This total distance
enhancement of mdm2 oncogene expression in human tumor cellsis the cutoff. The lists are then randomly permuted, holding fixed
containing a stabilized wild-type p53 protein. Cancer Res. 57, 3562–the number of elements of each list. The calculated p value is the
3568.percent of randomized groups that have a distance less than the
cutoff as determined by a large Monte Carlo simulation. Leach, F.S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J.D., Smith,
S., Hill, D.E., Sidransky, D., Kinzler, K.W., and Vogelstein, B. (1993).
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